Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about PVLA, unsubscribe in one click. Privacy
| PDUFA Date | Drug | Indication | Type | PoA |
|---|---|---|---|---|
| 2027-02-28 | QTORIN™ Rapamycin | microcystic lymphatic malformations | NDA | 66% |
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Sirolimus Topical Gel PTX-022 | Pachyonychia Congenita | Phase 3 · NCT05643872 | Recruiting |
| QTORIN 3.9% Rapamycin Anhydrous Gel | Microcystic Lymphatic Malformation | Phase 3 · NCT06239480 | Active not recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
PVLA holds $236.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $13.6M/quarter from operations, an estimated runway of 52.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 25 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PVLA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Kaupinen Wes | 5%+ holder (13D) | 1,644,869 | 11.25% | 2024-12-13 |
| Jennison Associates LLC | Institution (13G, 5%+) | 1,101,652 | 7.54% | 2026-09-30 |
| PRUDENTIAL FINANCIAL INC | Institution (13G, 5%+) | 962,374 | 6.58% | 2026-06-30 |
| Frazier Life Sciences Public Fund, L.P. | 5%+ holder (13G) | 848,376 | 5.80% | 2026-09-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 812,953 | 5.56% | 2026-06-30 |
| First Light Asset Management, LLC | Institution (13G, 5%+) | 769,117 | 5.26% | 2026-06-30 |
| George M Jenkins Director · +15,350 options |
Insider | 146,132 | 1.00% | 2026-10-12 |
| Elaine J Heron Director · +15,350 options |
Insider | 53,691 | 0.37% | 2026-02-27 |
| Matthew E Korenberg CFO, Treasurer · +210,223 options |
Insider | 1,000 | 0.01% | 2026-06-12 |
| Christopher P Kiritsy Director · +15,350 options |
Insider | 250 | 0.00% | 2026-09-02 |
Share count 14,618,457 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PVLA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →